Literature DB >> 19147812

Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q).

Ming Yan Xu1, Joanne Porte, Alan J Knox, Paul H Weinreb, Toby M Maher, Shelia M Violette, Robin J McAnulty, Dean Sheppard, Gisli Jenkins.   

Abstract

Activation of latent transforming growth factor beta (TGF-beta) by alphavbeta6 integrin is critical in the pathogenesis of lung injury and fibrosis. We have previously demonstrated that the stimulation of protease activated receptor 1 promotes alphavbeta6 integrin-mediated TGF-beta activation via RhoA, which is known to modulate cell contraction. However, whether other G protein-coupled receptors can also induce alphavbeta6 integrin-mediated TGF-beta activation is unknown; in addition, the alphavbeta6 integrin signaling pathway has not yet been fully characterized. In this study, we show that lysophosphatidic acid (LPA) induces alphavbeta6-mediated TGF-beta activation in human epithelial cells via both RhoA and Rho kinase. Furthermore, we demonstrate that LPA-induced alphavbeta6 integrin-mediated TGF-beta activity is mediated via the LPA2 receptor, which signals via G alpha(q). Finally, we show that the expression levels of both the LPA2 receptor and alphavbeta6 integrin are up-regulated and are spatially and temporally associated following bleomycin-induced lung injury. Furthermore, both the LPA2 receptor and alphavbeta6 integrin are up-regulated in the overlying epithelial areas of fibrosis in patients with usual interstitial pneumonia. These studies demonstrate that LPA induces alphavbeta6 integrin-mediated TGF-beta activation in epithelial cells via LPA2, G alpha(q), RhoA, and Rho kinase, and that this pathway might be clinically relevant to the development of lung injury and fibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147812      PMCID: PMC2671359          DOI: 10.2353/ajpath.2009.080160

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  60 in total

Review 1.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

2.  TGF-beta is a critical mediator of acute lung injury.

Authors:  J F Pittet; M J Griffiths; T Geiser; N Kaminski; S L Dalton; X Huang; L A Brown; P J Gotwals; V E Koteliansky; M A Matthay; D Sheppard
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 3.  G protein pathways.

Authors:  Susana R Neves; Prahlad T Ram; Ravi Iyengar
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

4.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis.

Authors:  Q Yu; I Stamenkovic
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

5.  Protein kinase C-alpha signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function.

Authors:  D Mehta; A Rahman; A B Malik
Journal:  J Biol Chem       Date:  2001-04-17       Impact factor: 5.157

6.  Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA.

Authors:  J J Contos; J Chun
Journal:  Genomics       Date:  2000-03-01       Impact factor: 5.736

7.  Synergistic stimulation of airway smooth muscle cell mitogenesis.

Authors:  T L Ediger; M L Toews
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

8.  Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis.

Authors:  D C Howell; N R Goldsack; R P Marshall; R J McAnulty; R Starke; G Purdy; G J Laurent; R C Chambers
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

9.  Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor.

Authors:  Mami Ikenoya; Hiroyoshi Hidaka; Takamitsu Hosoya; Masaaki Suzuki; Naoki Yamamoto; Yasuharu Sasaki
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372

10.  Bone abnormalities in latent TGF-[beta] binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-[beta] bioavailability.

Authors:  Branka Dabovic; Yan Chen; Cristina Colarossi; Hiroto Obata; Laura Zambuto; Mary Ann Perle; Daniel B Rifkin
Journal:  J Cell Biol       Date:  2002-01-14       Impact factor: 10.539

View more
  78 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 2.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

3.  TGF-beta receptor deletion in the renal collecting system exacerbates fibrosis.

Authors:  Leslie Gewin; Nada Bulus; Glenda Mernaugh; Gilbert Moeckel; Raymond C Harris; Harold L Moses; Ambra Pozzi; Roy Zent
Journal:  J Am Soc Nephrol       Date:  2010-06-24       Impact factor: 10.121

4.  Epithelial cells utilize cortical actin/myosin to activate latent TGF-β through integrin α(v)β(6)-dependent physical force.

Authors:  Marilyn M Giacomini; Mark A Travis; Makoto Kudo; Dean Sheppard
Journal:  Exp Cell Res       Date:  2012-01-28       Impact factor: 3.905

5.  A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.

Authors:  J S Swaney; C Chapman; L D Correa; K J Stebbins; R A Bundey; P C Prodanovich; P Fagan; C S Baccei; A M Santini; J H Hutchinson; T J Seiders; T A Parr; P Prasit; J F Evans; D S Lorrain
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

6.  Myofibroblast TGF-β Activation Measurement In Vitro.

Authors:  Joanne Porte; Gisli Jenkins; Amanda L Tatler
Journal:  Methods Mol Biol       Date:  2021

Review 7.  G Protein Coupled Receptor-mediated Transactivation of Extracellular Proteases.

Authors:  Allison E Schafer; Burns C Blaxall
Journal:  J Cardiovasc Pharmacol       Date:  2017-07       Impact factor: 3.105

8.  Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.

Authors:  Yong Huang; Shwu-Fan Ma; Milena S Espindola; Rekha Vij; Justin M Oldham; Gary B Huffnagle; John R Erb-Downward; Kevin R Flaherty; Beth B Moore; Eric S White; Tong Zhou; Jianrong Li; Yves A Lussier; MeiLan K Han; Naftali Kaminski; Joe G N Garcia; Cory M Hogaboam; Fernando J Martinez; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

9.  LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.

Authors:  Norihiko Sakai; Jerold Chun; Jeremy S Duffield; Takashi Wada; Andrew D Luster; Andrew M Tager
Journal:  FASEB J       Date:  2013-01-15       Impact factor: 5.191

10.  Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by αvβ6 integrin-mediated signaling in ovarian cancer.

Authors:  Baoyao Xue; Weiguang Wu; Kan Huang; Tingting Xie; Xiaobo Xu; Hongju Zhang; Chunlei Qi; Junli Ge; Yuecheng Yu
Journal:  Mol Cell Biochem       Date:  2013-04-25       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.